{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:18:33Z","timestamp":1769476713769,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272978"],"award-info":[{"award-number":["82272978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation Project of Hubei Province","award":["2021CFB484"],"award-info":[{"award-number":["2021CFB484"]}]},{"name":"Open Foundation of Hubei Province Key Laboratory of Tumor Microenvironment and Immunotherapy","award":["2024KZL07"],"award-info":[{"award-number":["2024KZL07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01163-z","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T13:45:09Z","timestamp":1769435109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression"],"prefix":"10.1007","volume":"49","author":[{"given":"Wen-wen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-ran","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan-shuang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-han","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-ling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"E. Comp\u00e9rat, M.B. Amin, R. Cathomas, A. Choudhury, De M. Santis, A. Kamat, A. Stenzl, H.C. Thoeny, J.A. Witjes, Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 400, 1712\u20131721 (2022)","journal-title":"Lancet"},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/551S33a","volume":"551","author":"M Grayson","year":"2017","unstructured":"M. Grayson, Bladder cancer. Nature. 551, S33 (2017)","journal-title":"Nature"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","volume":"69","author":"J Dobruch","year":"2016","unstructured":"J. Dobruch, S. Daneshmand, M. Fisch, Y. Lotan, A.P. Noon, M.J. Resnick, S.F. Shariat, A.R. Zlotta, S.A. Boorjian, Gender and bladder cancer: A collaborative review of Etiology, Biology, and outcomes. Eur. Urol. 69, 300\u2013310 (2016)","journal-title":"Eur. Urol."},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"J.W.F. Catto, B. Tran, M. Roupr\u00eat, J.E. Gschwend, Y. Loriot, H. Nishiyama, J.P. Redorta, S. Daneshmand, S.A. Hussain, H.J. Cutuli et al., Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann. Oncol. 35, 98\u2013106 (2024)","journal-title":"Ann. Oncol."},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"A. Lopez-Beltran, M.S. Cookson, B.J. Guercio, L. Cheng, Advances in diagnosis and treatment of bladder cancer. Bmj. 384, e076743 (2024)","journal-title":"Bmj"},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","volume":"15","author":"FC de Jong","year":"2023","unstructured":"de F.C. Jong, T.D. Laajala, R.F. Hoedemaeker, K.R. Jordan, van der A.C.J. Made, E.R. Boev\u00e9, van der D.K.E. Schoot, B. Nieuwkamer, E.A.M. Janssen, T. Mahmoudi et al., Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin. Sci. Transl Med. 15, eabn4118 (2023)","journal-title":"Sci. Transl Med."},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"R.H. Mak, D. Hunt, W.U. Shipley, J.A. Efstathiou, W.J. Tester, M.P. Hagan, D.S. Kaufman, N.M. Heney, A.L. Zietman, Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J. Clin. Oncol. 32, 3801\u20133809 (2014)","journal-title":"J. Clin. Oncol."},{"key":"1163_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"J. Alfred Witjes, H. Max Bruins, A. Carri\u00f3n, R. Cathomas, E. Comp\u00e9rat, J.A. Efstathiou, R. Fietkau, G. Gakis, A. Lorch, A. Martini et al., European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024)","journal-title":"Eur. Urol."},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","volume":"78","author":"AG Robertson","year":"2020","unstructured":"A.G. Robertson, C.S. Groeneveld, B. Jordan, X. Lin, K.A. McLaughlin, A. Das, L.A. Fall, D. Fantini, T.J. Taxter, L.S. Mogil et al., Identification of differential tumor subtypes of T1 bladder cancer. Eur. Urol. 78, 533\u2013537 (2020)","journal-title":"Eur. Urol."},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00428-014-1596-4","volume":"465","author":"Y Neuzillet","year":"2014","unstructured":"Y. Neuzillet, van B.W. Rhijn, N.L. Prigoda, B. Bapat, L. Liu, P.J. Bostrom, N.E. Fleshner, B.L. Gallie, A.R. Zlotta, M.A. Jewett, van der T.H. Kwast, FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. Virchows Arch. 465, 207\u2013213 (2014)","journal-title":"Virchows Arch."},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"K. Komura, K. Hirosuna, S. Tokushige, T. Tsujino, K. Nishimura, M. Ishida, T. Hayashi, A. Ura, T. Ohno, S. Yamazaki et al., The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol. Cancer. 22, 185 (2023)","journal-title":"Mol. Cancer"},{"key":"1163_CR12","doi-asserted-by":"crossref","unstructured":"Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, et al. FGFR Inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J. Clin. Invest. 134, e169241 (2024)","DOI":"10.1172\/JCI169241"},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","volume":"29","author":"BJ Guercio","year":"2023","unstructured":"B.J. Guercio, M. Sarfaty, M.Y. Teo, N. Ratna, C. Duzgol, S.A. Funt, C.H. Lee, D.H. Aggen, A.M. Regazzi, Z. Chen et al., Clinical and genomic landscape of FGFR3-Altered urothelial carcinoma and treatment outcomes with erdafitinib: A Real-World experience. Clin. Cancer Res. 29, 4586\u20134595 (2023)","journal-title":"Clin. Cancer Res."},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2023.05.037","volume":"85","author":"CS Groeneveld","year":"2024","unstructured":"C.S. Groeneveld, V. Sanchez-Quiles, F. Dufour, M. Shi, F. Dingli, R. Nicolle, E. Chapeaublanc, P. Poullet, D. Jeffery, C. Krucker et al., Proteogenomic characterization of bladder cancer reveals sensitivity to apoptosis induced by tumor necrosis Factor-related apoptosis-inducing ligand in FGFR3-mutated tumors. Eur. Urol. 85, 483\u2013494 (2024)","journal-title":"Eur. Urol."},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/annonc\/mdw636","volume":"28","author":"P Chandrani","year":"2017","unstructured":"P. Chandrani, K. Prabhash, R. Prasad, V. Sethunath, M. Ranjan, P. Iyer, J. Aich, H. Dhamne, D.N. Iyer, P. Upadhyay et al., Drug-sensitive FGFR3 mutations in lung adenocarcinoma. Ann. Oncol. 28, 597\u2013603 (2017)","journal-title":"Ann. Oncol."},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"10914","DOI":"10.1038\/s41467-024-55331-6","volume":"15","author":"PA Bannier","year":"2024","unstructured":"P.A. Bannier, C. Saillard, P. Mann, M. Touzot, C. Maussion, C. Matek, N. Kl\u00fcmper, J. Breyer, R. Wirtz, D. Sikic et al., AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. Nat. Commun. 15, 10914 (2024)","journal-title":"Nat. Commun."},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.eururo.2020.08.016","volume":"78","author":"R Flippot","year":"2020","unstructured":"R. Flippot, Y. Loriot, The FGFR3 story in bladder cancer: another piece of the puzzle? Eur. Urol. 78, 688\u2013689 (2020)","journal-title":"Eur. Urol."},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"W. Jing, G. Wang, Z. Cui, G. Xiong, X. Jiang, Y. Li, W. Li, B. Han, S. Chen, B. Shi, FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-Mediated bladder cancer immune surveillance. Cancer Res. 82, 114\u2013129 (2022)","journal-title":"Cancer Res."},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1172\/JCI38948","volume":"119","author":"Y Hadari","year":"2009","unstructured":"Y. Hadari, J. Schlessinger, FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J. Clin. Invest. 119, 1077\u20131079 (2009)","journal-title":"J. Clin. Invest."},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7150\/thno.16357","volume":"7","author":"S Sun","year":"2017","unstructured":"S. Sun, Y. Wang, R. Zhou, Z. Deng, Y. Han, X. Han, W. Tao, Z. Yang, C. Shi, D. Hong et al., Targeting and regulating of an oncogene via nanovector delivery of MicroRNA using Patient-Derived xenografts. Theranostics. 7, 677\u2013693 (2017)","journal-title":"Theranostics"},{"key":"1163_CR21","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1158\/1078-0432.CCR-13-3336","volume":"20","author":"X Du","year":"2014","unstructured":"X. Du, B.C. Lin, Q.R. Wang, H. Li, E. Ingalla, J. Tien, I. Rooney, A. Ashkenazi, E. Penuel, J. Qing, MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer. Clin. Cancer Res. 20, 6324\u20136335 (2014)","journal-title":"Clin. Cancer Res."},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"eadn1452","DOI":"10.1126\/sciimmunol.adn1452","volume":"9","author":"A Balasubramanian","year":"2024","unstructured":"A. Balasubramanian, A.Y. Hsu, L. Ghimire, M. Tahir, P. Devant, P. Fontana, G. Du, X. Liu, D. Fabin, H. Kambara et al., The palmitoylation of gasdermin D directs its membrane translocation and pore formation during pyroptosis. Sci. Immunol. 9, eadn1452 (2024)","journal-title":"Sci. Immunol."},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1038\/s41467-023-42476-z","volume":"14","author":"M Gu","year":"2023","unstructured":"M. Gu, H. Jiang, M. Tan, L. Yu, N. Xu, Y. Li, H. Wu, Q. Hou, C. Dai, Palmitoyltransferase DHHC9 and acyl protein thioesterase APT1 modulate renal fibrosis through regulating \u03b2-catenin palmitoylation. Nat. Commun. 14, 6682 (2023)","journal-title":"Nat. Commun."},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.7150\/ijbs.72244","volume":"18","author":"Z Liu","year":"2022","unstructured":"Z. Liu, M. Xiao, Y. Mo, H. Wang, Y. Han, X. Zhao, X. Yang, Z. Liu, B. Xu, Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy. Int. J. Biol. Sci. 18, 3447\u20133457 (2022)","journal-title":"Int. J. Biol. Sci."},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1080\/15548627.2024.2386915","volume":"20","author":"F Wei","year":"2024","unstructured":"F. Wei, Y. Wang, J. Yao, L. Mei, X. Huang, H. Kong, J. Chen, X. Chen, L. Liu, Z. Wang et al., ZDHHC7-mediated S-palmitoylation of ATG16L1 facilitates LC3 lipidation and autophagosome formation. Autophagy. 20, 2719\u20132737 (2024)","journal-title":"Autophagy"},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"e2403392121","DOI":"10.1073\/pnas.2403392121","volume":"121","author":"Y Liu","year":"2024","unstructured":"Y. Liu, D. Hou, W. Chen, X. Lu, G.P. Komaniecki, Y. Xu, T. Yu, S.M. Zhang, M.E. Linder, H. Lin, MAVS Cys508 palmitoylation promotes its aggregation on the mitochondrial outer membrane and antiviral innate immunity. Proc. Natl. Acad. Sci. U S A 121, e2403392121 (2024)","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"1163_CR27","doi-asserted-by":"crossref","unstructured":"Y.R. Qian, Y.J. Zhao, F. Zhang, Protein palmitoylation: biological functions, disease, and therapeutic targets. MedComm (2020), 6, e70096 (2025)","DOI":"10.1002\/mco2.70096"},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrm2728","volume":"10","author":"H Stenmark","year":"2009","unstructured":"H. Stenmark, Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell. Biol. 10, 513\u2013525 (2009)","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"1163_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15548627.2024.2374699","volume":"21","author":"K Haga","year":"2025","unstructured":"K. Haga, M. Fukuda, Comprehensive knockout analysis of the RAB family small GTPases reveals an overlapping role of RAB2 and RAB14 in autophagosome maturation. Autophagy. 21, 21\u201336 (2025)","journal-title":"Autophagy"},{"key":"1163_CR30","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.1002\/jev2.12465","volume":"13","author":"JD Mason","year":"2024","unstructured":"J.D. Mason, E. Marks, S.J. Fan, K. McCormick, C. Wilson, A.L. Harris, F.C. Hamdy, C. Cunningham, D.C.I. Goberdhan, Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer. J. Extracell. Vesicles. 13, e12465 (2024)","journal-title":"J. Extracell. Vesicles"},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"e56240","DOI":"10.15252\/embr.202256240","volume":"24","author":"I Joseph","year":"2023","unstructured":"I. Joseph, J. Flores, V. Farrell, J. Davis, J. Bianchi-Smak, Q. Feng, S. Goswami, X. Lin, Z. Wei, K. Tong et al., RAB11A and RAB11B control mitotic spindle function in intestinal epithelial progenitor cells. EMBO Rep. 24, e56240 (2023)","journal-title":"EMBO Rep."},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"e2501177122","DOI":"10.1073\/pnas.2501177122","volume":"122","author":"D Li","year":"2025","unstructured":"D. Li, H. Chen, G. Vale, N. Elghobashi-Meinhardt, A. Hatton, S. Rong, J.G. McDonald, X. Li, Molecular insights into human phosphatidylserine synthase 2 and its regulation of SREBP pathways. Proc. Natl. Acad. Sci. U S A 122, e2501177122 (2025)","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"1163_CR33","doi-asserted-by":"publisher","first-page":"eadi4191","DOI":"10.1126\/sciimmunol.adi4191","volume":"9","author":"MP Plebanek","year":"2024","unstructured":"M.P. Plebanek, Y. Xue, Y.V. Nguyen, N.C. DeVito, X. Wang, A. Holtzhausen, G.M. Beasley, B. Theivanthiran, B.A. Hanks, A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci. Immunol. 9, eadi4191 (2024)","journal-title":"Sci. Immunol."},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s42255-025-01291-0","volume":"7","author":"M Xu","year":"2025","unstructured":"M. Xu, S.Y. Jiang, S. Tang, M. Zhu, Y. Hu, J. Li, J. Yan, C. Qin, D. Tan, Y. An et al., Nuclear SREBP2 condensates regulate the transcriptional activation of lipogenic genes and cholesterol homeostasis. Nat. Metab. 7, 1034\u20131051 (2025)","journal-title":"Nat. Metab."},{"key":"1163_CR35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.immuni.2018.08.021","volume":"49","author":"C Guo","year":"2018","unstructured":"C. Guo, Z. Chi, D. Jiang, T. Xu, W. Yu, Z. Wang, S. Chen, L. Zhang, Q. Liu, X. Guo et al., Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity. 49, 842\u2013856e847 (2018)","journal-title":"Immunity"},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1038\/s41467-024-49105-3","volume":"15","author":"H Zhang","year":"2024","unstructured":"H. Zhang, Y. Sun, Z. Wang, X. Huang, L. Tang, K. Jiang, X. Jin, ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression. Nat. Commun. 15, 4642 (2024)","journal-title":"Nat. Commun."},{"key":"1163_CR37","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1021\/acs.chemrev.8b00467","volume":"119","author":"MD Paul","year":"2019","unstructured":"M.D. Paul, K. Hristova, The RTK interactome: overview and perspective on RTK heterointeractions. Chem. Rev. 119, 5881\u20135921 (2019)","journal-title":"Chem. Rev."},{"key":"1163_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cytogfr.2019.10.004","volume":"49","author":"MD Paul","year":"2019","unstructured":"M.D. Paul, K. Hristova, The transition model of RTK activation: A quantitative framework for Understanding RTK signaling and RTK modulator activity. Cytokine Growth Factor. Rev. 49, 23\u201331 (2019)","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1163_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"C. Tomuleasa, A.B. Tigu, R. Munteanu, C.S. Moldovan, D. Kegyes, A. Onaciu, D. Gulei, G. Ghiaur, H. Einsele, C.M. Croce, Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal. Transduct. Target. Ther. 9, 201 (2024)","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1163_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Z. Du, C.M. Lovly, Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer. 17, 58 (2018)","journal-title":"Mol. Cancer"},{"key":"1163_CR41","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41467-025-57583-2","volume":"16","author":"F Chen","year":"2025","unstructured":"F. Chen, H. Tang, C. Li, R. Kang, D. Tang, J. Liu, CYP51A1 drives resistance to pH-dependent cell death in pancreatic cancer. Nat. Commun. 16, 2278 (2025)","journal-title":"Nat. Commun."},{"key":"1163_CR42","doi-asserted-by":"publisher","first-page":"102732","DOI":"10.1016\/j.redox.2023.102732","volume":"63","author":"Y Kong","year":"2023","unstructured":"Y. Kong, M. Wu, X. Wan, M. Sun, Y. Zhang, Z. Wu, C. Li, X. Liang, L. Gao, C. Ma, X. Yue, Lipophagy-mediated cholesterol synthesis Inhibition is required for the survival of hepatocellular carcinoma under glutamine deprivation. Redox Biol. 63, 102732 (2023)","journal-title":"Redox Biol."},{"key":"1163_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/15548627.2023.2254191","volume":"20","author":"Q Ren","year":"2024","unstructured":"Q. Ren, Q. Sun, J. Fu, Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease. Autophagy. 20, 221\u2013241 (2024)","journal-title":"Autophagy"},{"key":"1163_CR44","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.3168\/jds.2008-1932","volume":"92","author":"AK Kadegowda","year":"2009","unstructured":"A.K. Kadegowda, M. Bionaz, L.S. Piperova, R.A. Erdman, J.J. Loor, Peroxisome proliferator-activated receptor-gamma activation and long-chain fatty acids alter lipogenic gene networks in bovine mammary epithelial cells to various extents. J. Dairy. Sci. 92, 4276\u20134289 (2009)","journal-title":"J. Dairy. Sci."},{"key":"1163_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13059-021-02456-2","volume":"22","author":"M Shi","year":"2021","unstructured":"M. Shi, K. You, T. Chen, C. Hou, Z. Liang, M. Liu, J. Wang, T. Wei, J. Qin, Y. Chen et al., Quantifying the phase separation property of chromatin-associated proteins under physiological conditions using an anti-1,6-hexanediol index. Genome Biol. 22, 229 (2021)","journal-title":"Genome Biol."},{"key":"1163_CR46","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Y. Loriot, N. Matsubara, S.H. Park, R.A. Huddart, E.F. Burgess, N. Houede, S. Banek, V. Guadalupi, J.H. Ku, B.P. Valderrama et al., Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl. J. Med. 389, 1961\u20131971 (2023)","journal-title":"N Engl. J. Med."},{"key":"1163_CR47","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-23-1065","volume":"83","author":"Y Ouyang","year":"2023","unstructured":"Y. Ouyang, Z. Ou, W. Zhong, J. Yang, S. Fu, N. Ouyang, J. Chen, L. Xu, D. Wu, J. Qian et al., FGFR3 alterations in bladder cancer stimulate Serine synthesis to induce Immune-Inert macrophages that suppress T-cell recruitment and activation. Cancer Res. 83, 4030\u20134046 (2023)","journal-title":"Cancer Res."},{"key":"1163_CR48","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","volume":"30","author":"J Rod\u00f3n","year":"2024","unstructured":"J. Rod\u00f3n, S. Damian, M. Furqan, J. Garc\u00eda-Donas, H. Imai, A. Italiano, I. Spanggaard, M. Ueno, T. Yokota, M.L. Veronese et al., Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat. Med. 30, 1645\u20131654 (2024)","journal-title":"Nat. Med."},{"key":"1163_CR49","doi-asserted-by":"crossref","unstructured":"M.K. Chen, H. Yamaguchi, Y. Gao, W. Xia, J.T. Chang, Y.C. Hsiao, T.W. Shegute, Z.S. Lin, C.S. Wu, Y.H. Wang et al., FGFR3-induced Y158 PARP1 phosphorylation promotes PARP-inhibitor resistance via BRG1\/MRE11-mediated DNA repair in breast cancer models. J. Clin. Invest. 135, e173757 (2025)","DOI":"10.1172\/JCI173757"},{"key":"1163_CR50","doi-asserted-by":"publisher","first-page":"11932","DOI":"10.1038\/ncomms11932","volume":"7","author":"K Mukai","year":"2016","unstructured":"K. Mukai, H. Konno, T. Akiba, T. Uemura, S. Waguri, T. Kobayashi, G.N. Barber, H. Arai, T. Taguchi, Activation of STING requires palmitoylation at the golgi. Nat. Commun. 7, 11932 (2016)","journal-title":"Nat. Commun."},{"key":"1163_CR51","doi-asserted-by":"publisher","first-page":"e2412895","DOI":"10.1002\/advs.202412895","volume":"12","author":"Y He","year":"2025","unstructured":"Y. He, S. Li, L. Jiang, K. Wu, S. Chen, L. Su, C. Liu, P. Liu, W. Luo, S. Zhong, Z. Li, Palmitic acid accelerates endothelial cell injury and cardiovascular dysfunction via palmitoylation of PKM2. Adv. Sci. (Weinh). 12, e2412895 (2025)","journal-title":"Adv. Sci. (Weinh)"},{"key":"1163_CR52","doi-asserted-by":"publisher","first-page":"6898","DOI":"10.7150\/thno.78377","volume":"12","author":"B Zhou","year":"2022","unstructured":"B. Zhou, Y. Wang, L. Zhang, X. Shi, H. Kong, M. Zhang, Y. Liu, X. Shao, Z. Liu, H. Song et al., The palmitoylation of AEG-1 dynamically modulates the progression of hepatocellular carcinoma. Theranostics. 12, 6898\u20136914 (2022)","journal-title":"Theranostics"},{"key":"1163_CR53","doi-asserted-by":"publisher","first-page":"103376","DOI":"10.1016\/j.redox.2024.103376","volume":"77","author":"Y Ma","year":"2024","unstructured":"Y. Ma, X. Yuan, A. Wei, X. Li, A. Patar, S. Su, S. Wang, G. Ma, J. Zhu, E. Kong, Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1. Redox Biol. 77, 103376 (2024)","journal-title":"Redox Biol."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01163-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01163-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01163-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:03:10Z","timestamp":1769439790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01163-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01163-z","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of human samples in this study was approved by the Ethics Committee of the Life Sciences Medical Ethics Committee of Wuhan University (Approval No. 20220007). All patients gave written informed consent before inclusion in this study. All animal experiments were approved by the Ethics Committee of the Life Sciences Medical Ethics Committee of Wuhan University and were performed in accordance with the guidelines approved by Wuhan University Institutional Animal Care and Use Committee (IACUC) (approval number WAEF-2024-0035). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}